Table 1.
Clinicopathological patient characteristics and correlation with B7-H3 status.
| Characteristics | Valid/Missing | B7-H3 Low | B7-H3 High | p-Value | |||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | ||
| Total | 96 | (100) | 55 | (57.3) | 41 | (42.7) | |
| Gender | 96/0 | 0.061 2 | |||||
| Male | 57 | (59.4) | 28 | (49.1) | 29 | (50.9) | |
| Female | 39 | (40.6) | 27 | (69.2) | 12 | (30.8) | |
| Age | 96/0 | 0.410 1 | |||||
| <68 years | 50 | (52.1) | 31 | (62.0) | 19 | (38.0) | |
| ≥68 years | 46 | (47.9) | 24 | (52.2) | 22 | (47.8) | |
| Location | 95/1 | 0.003 2 | |||||
| Proximal stomach | 37 | (38.9) | 14 | (37.8) | 23 | (62.2) | |
| Distal stomach | 58 | (61.1) | 40 | (69.0) | 18 | (31.0) | |
| Laurén phenotype | 96/0 | <0.001 2 | |||||
| Intestinal | 48 | (50.0) | 17 | (35.4) | 31 | (64.6) | |
| Diffuse | 27 | (28.1) | 25 | (92.6) | 2 | (7.4) | |
| Mixed | 6 | (6.3) | 2 | (33.3) | 4 | (66.7) | |
| Unclassified | 15 | (15.6) | 11 | (73.3) | 4 | (26.7) | |
| Grade | 90/6 | 0.173 1 | |||||
| G1/G2 | 17 | (18.9) | 7 | (41.2) | 10 | (58.8) | |
| G3/G4 | 73 | (81.1) | 45 | (61.6) | 28 | (38.4) | |
| pT category | 96/0 | 0.013 1 | |||||
| pT1/pT2 | 22 | (22.9) | 18 | (81.8) | 4 | (18.2) | |
| pT3/pT4 | 74 | (77.1) | 37 | (50.0) | 37 | (50.0) | |
| pN category | 96/0 | 1.000 1 | |||||
| pN0 | 32 | (33.3) | 18 | (56.2) | 14 | (43.8) | |
| pN+ | 64 | (66.7) | 37 | (57.8) | 27 | (42.2) | |
| M category | 91/5 | 0.591 1 | |||||
| M0 | 74 | (81.3) | 41 | (55.4) | 33 | (44.6) | |
| M1 | 17 | (18.7) | 11 | (64.7) | 6 | (35.3) | |
| UICC stage | 91/5 | 0.778 1 | |||||
| IA/IB | 16 | (17.6) | 13 | (81.2) | 3 | (18.8) | |
| IIA/IIB | 25 | (27.4) | 10 | (40.0) | 15 | (60.0) | |
| IIIA/IIIB/IIIC | 33 | (36.3) | 18 | (54.5) | 15 | (45.5) | |
| IV | 17 | (18.7) | 11 | (64.7) | 6 | (35.3) | |
| pR status | 89/7 | 0.231 1 | |||||
| pR0 | 82 | (92.1) | 45 | (54.9) | 37 | (45.1) | |
| pR1/pR2 | 7 | (7.9) | 6 | (85.7) | 1 | (14.3) | |
| Overall survival (months) | 0.784 3 | ||||||
| Total/events/censored | 89/64/25 | 51/38/19 | 38/26/12 | ||||
| Median survival | 17.5 | 17.5 | 16.6 | ||||
| 95% C.I. | 10.7–24.3 | 9.0–26.0 | 10.3–22.9 | ||||
| Cause-specific survival (months) | 0.990 3 | ||||||
| Total/events/censored | 82/50/32 | 47/28/19 | 35/22/13 | ||||
| Median survival | 18.4 | 17.5 | 18.4 | ||||
| 95% C.I. | 9.6–27.3 | 6.6–28.5 | 12.8–24.1 | ||||
1 Kendall’s tau test, 2 Fisher’s exact test, 3 log-rank test; UICC, Union for International Cancer Control.